{"id":78250,"date":"2026-03-09T00:05:17","date_gmt":"2026-03-09T00:05:17","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/"},"modified":"2026-03-09T00:05:17","modified_gmt":"2026-03-09T00:05:17","slug":"xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/","title":{"rendered":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026"},"content":{"rendered":"
\n

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV<\/sub>7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Conference Call\/Webcast Information:<\/strong><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Date:<\/strong><\/td>\nMonday, March 9, 2026<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Time:<\/strong><\/td>\n8:00 am ET (5:00 am PT)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Webcast:<\/strong><\/td>\nPre-register here<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Dial-In:<\/strong><\/td>\n(800) 715-9871 toll-free or (646) 307-1963 for international callers<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Conference ID:<\/strong><\/td>\n7885306<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

A live webcast of the company presentation will be available on the Investors<\/a> section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.<\/p>\n

About Xenon Pharmaceuticals Inc.<\/u><\/strong><\/p>\n

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon\u2019s lead molecule, azetukalner, is a novel, potent KV<\/sub>7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV<\/sub>7 and NaV<\/sub>1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.<\/p>\n

Contacts<\/u><\/strong><\/p>\n

For Investors:<\/em>
Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com<\/a><\/p>\n

For Media:<\/em>
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com<\/a><\/p>\n

\"\"<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in […]\n","protected":false},"author":1,"featured_media":78251,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-78250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\nXenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biop\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T00:05:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/ZTk3ZDljMmItYmU1ZS00ZWNmLTlhMjQtOGUzNTU4YWY5NDMyLTEwMjI5NTMtMjAyNi0wMy0wOC1lbg==\/tiny\/Xenon-Pharmaceuticals-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026\",\"datePublished\":\"2026-03-09T00:05:17+00:00\",\"dateModified\":\"2026-03-09T00:05:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\",\"name\":\"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-03-09T00:05:17+00:00\",\"dateModified\":\"2026-03-09T00:05:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/","og_locale":"en_US","og_type":"article","og_title":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026","og_description":"VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biop","og_url":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-03-09T00:05:17+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/ZTk3ZDljMmItYmU1ZS00ZWNmLTlhMjQtOGUzNTU4YWY5NDMyLTEwMjI5NTMtMjAyNi0wMy0wOC1lbg==\/tiny\/Xenon-Pharmaceuticals-Inc-.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026","datePublished":"2026-03-09T00:05:17+00:00","dateModified":"2026-03-09T00:05:17+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/"},"wordCount":299,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/","url":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/","name":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-03-09T00:05:17+00:00","dateModified":"2026-03-09T00:05:17+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=78250"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78250\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/78251"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=78250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=78250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=78250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}